<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">


Blood-based proteomic solutions

We are the leader in discovering and commercializing clinically relevant blood-based proteomic tests for lung cancer.

The Cancer Ecosystem

While genomic data uncovers the potential genetic drivers of cancer (tumor), proteomic data profiles the patient’s (host) immune response to their cancer. Both are critical elements for interpreting the real-time complexity of the cancer disease state (cancer ecosystem).


Image adapted from Chen and Mellman 2016 for educational purposes.

Our Comprehensive Blood-Based Proteomic Solution Platforms

We are experts at profiling the patient's immune response to their cancer with blood-based proteomic solutions in addition to traditional genomic insights. Our mass spectrometry and machine learning expertise allows us to identify clinically relevant proteomic differences in patient populations to help guide treatment strategy.

MALDI-ToF Mass Spectrometry

We use Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI-ToF) mass spectrometry to broadly interrogate the circulating proteome without the need to identify specific proteins in advance. ​

How we apply Maldi-Tof

Liquid Chromatography (LC-MS) Mass Spectrometry

We use LC-MS for both targeted and discovery proteomics. This includes  quantification of predefined highly-multiplexed sets of proteins with MRM-MS and unbiased discovery proteomics with SWATH / DIA-MS.

How we apply LC-MS

Enzyme-Linked Immunosorbent Assay (ELISA)

We use ELISA as a targeted and quantitative method for interpreting a patient's immune response to cancer by measuring blood levels of autoantibodies to tumor-associated antigens.

How we apply ELISA

We use mass spectrometry to decipher the circulating proteome with both top-down and bottom-up approaches.

Top-Down Proteomics:​ Intact protein analysis

  • Highly multiplexed & high throughput​
  • Identifies splice variants & PTMs​
  • Highly reproducible
  • Established clinical diagnostic with VeriStrat®
Learn more about MALDI

Bottom-Up Proteomics: Peptide analysis

  • Quantitative and precise
  • Highly multiplexed targeted proteomics​
  • Established clinical tests (Nodify CDT™ and Nodify XL2™ proteomic tests)

Learn more about LC-MS

Learn more about ELISA

“Together, cancer cells and host cells form an ecosystem. Initially, the cancer cells are an invasive species to a new niche or environment. Eventually, the cancer-cell [to] host-cell interactions create a new environment. Ask not just what the cancer is doing to you. Ask what you are doing to the cancer.”

- Mukherjee S. "Cancer's Invasion Equation." The New Yorker, September 2017

Get in touch

Contact us

What we do

Learn More

Data library

Discover more

Interested in another topic?